Actinium Pharmaceuticals, Inc. (AMEX:ATNM) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on October 16, 2026.
At publication ·
Actinium Pharmaceuticals, Inc. (AMEX:ATNM) · proxy filed
At a glance
Actinium Pharmaceuticals, Inc. (AMEX:ATNM) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on October 16, 2026.
The Healthcare company's proxy statement provides information for shareholders ahead of the annual meeting, including board nominations, executive compensation, and proposals for shareholder vote.
Actinium Pharmaceuticals, Inc.'s stock currently trades at $1.13 with a market capitalization of $45.5M.
SEC filings provide mandatory disclosures that give investors access to the same material information available to institutional investors. Reviewing Actinium Pharmaceuticals, Inc.'s filings alongside price action and analyst commentary provides a more complete picture of the company's current situation.
All SEC filings for Actinium Pharmaceuticals, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ATNM Stock Page
Browse all filings on our ATNM SEC filings page.
Public companies like Actinium Pharmaceuticals, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
Current market data
AMEX · ATNM
$1.40
Down: -$0.12 · -7.89%
Live quote updated
Keep reading
